Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2022.475 | Translating multi-omic discoveries to transform diabetes care and reduce diabetic complications Substudy 1: A randomized controlled trial to evaluate the clinical utility of communicating polygenic risk scores in diabetes | Prof. MA Ronald |
| 2013.042 | Identification of clinical and genetic predictors of hyperglycaemia and impaired beta-cell function in Chinese children- an analysis using mother-offspring pairs | Prof. MA Ronald |
| 2011.118 | Genetic determinants of obesity and cardiometabolic traits in Chinese adolescents | Professor Ma Ronald |
| 2008.519 | The role of neurohormonal dysregulation in the transgenerational effects of maternal diabetes | Prof Ma Ronald |
| 2013.304 | An integrated trans-omics approach to diabetic cardio-renal complications: from novel discoveries to personalized medicine Substudy 2: The Hong Kong Diabetes Biobank | Prof. MA Ronald |
| 2011.047 | Identification of genetic variants assocaited with atrial fibrillation and its effect in subjects with diabetes | Prof Ma Ronald |
| 2008.518 | Progression of cardio-metabolic risk factors in Chinese women with Polycystic Ovary Syndrome | Prof Ma Ronald |
| 2011.302 | Identificatin and large-scale replication of genetic predictors of diabetic kidney disease and diabetic retinopathy in the Chinese population | Prof Ma Ronald |
| 2013.447 | Developing a Metagenomic Next-Generation Sequencing Software Platform for Discovering Biomarkers with Application to Obesity and Type 2 Diabetes | Prof. MA Ronald |
| 2011.354 | Identification of epigenetic markers associated with maternal diabetes and obesity | Prof. MA Ronald |
| 2013.251 | An integrated trans-omics approach to diabetic cardio-renal complications: from novel discoveries to personalized medicine - Substudy 1: Transcriptome analysis of diabetic kidney disease | Prof. MA Ronald |
| 2013.187 | An integrated trans-omics approach to diabetic cardio-renal complications: from novel discoveries to personalized medicine | Prof. MA Ronald |
| 2012.325 | Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Follow-up Study | Prof. MA Ronald Ching Wan |
| 2011.407 | The cardiometabolic risk amongst women with a prior history of hypertensive disorder | Prof. MA Ronald Ching Wan |
| 2014.424 | DECLARE Dapagliflozin Effect on CardiovascuLAR Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes | Prof. MA Ronald Ching Wan |
| 2013.500 | Gestational age specific thyroid function reference range in Hong Kong | Prof. MA Ronald Ching Wan |
| 2015.641 | The impact of gestational diabetes mellitus and vitamin D deficiency during pregnancy on children’s cardiometabolic risk and methylation | Prof. MA Ronald Ching Wan |
| 2015.547 | A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care |
Prof. MA Ronald Ching Wan 馬青雲 |
| 2017.268 | A randomized clinical trial using a postnatal lifestyle modification program to improve diet, adiposity and metabolic outcome in mothers with gestational diabetes and their offspring | Prof. MA Ronald Ching Wan |
| 2017.291 | Validation of a novel assay for measurements of biologically active Angiotensin peptides(AngP) by Liquid chromatography Mass Spectrometry(LCMS)for the screening and diagnosis of Conn’s syndrome in hypertensive patients |
Prof. MA Ronald Ching Wan 馬青雲 |
| 2016.442 | RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH ERTUGLIFLOZIN (MK-8835/PF-04971729) IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED VASCULAR DISEASE, THE VERTIS CV STUDY |
Prof. MA Ronald Ching Wan 馬青雲 |
| 2024.165 | Development and validation of a methylation signature for polycystic ovary syndrome | Prof. MA Ronald Ching Wan |
| 2024.252 | Lifecourse trajectory of adiposity and beta-cell function in a multi-ethnic population- analysis from the Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) Study and Hyperglycaemia and Adverse Pregnancy Outcome Follow-up Study (HAPOFUS) | Prof. MA Ronald Ching Wan |
| 2008.017 | Maternal Hyperglycaemia and Cardio-Metabolic Risk of Children Offspring - A Follow Up on HAPO Study | Prof. MA Ronald Ching Wan |
| 2012.546 | A Phase III, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of MK-3102 Versus Placebo in Subjects with Type 2 Diabetes Mellitus with Moderate or Severe Chronic Kidney Disease or Kidney Failure on Dialysis Who Have Inadequate Glycemic Control | Prof. MA Ronald Ching Wan |
| 2010.227 | The Observational Registry Collecting Data On Gastroenteropancreatic Neuroendocrine Tumor Patients (GEP-NET Registry) | Dr. MA Ronald Ching Wan |
| 2014.318 | A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients with Type 2 Diabetes Mellitus [THEMIS - Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study] | Prof. MA Ronald Ching Wan |
| 2011.613 | A Randomized Clinical Trial to Compare a Strategy Utilizing Genetic Testing and Personalized Risk Counselling with Standard Care on Patient Empowerment, Risk Factors Control and the Risk of Diabetic Complications | Prof. MA Ronald Ching Wan |
| 2021.559 | The use of NT-proBNP for stratifying risk of cardio-renal complications in Chinese patients with Type 2 diabetes |
Prof. MA Ronald Ching Wan 馬青雲 |
| 2021.441 | A non-blinded retrospective biomarker add-on study to FIGARO-DKD for Bioprofiling the pharMacodynamic response to finerenone in FIGARO-DKD subjects (FIGARO-BM) |
Dr. MA Ronald Ching Wan 馬青雲 |
| 2022.207 | The impact of early-life exposure to metabolic abnormalities on pubertal development - from epidemiological analyses to mechanisms |
Prof. MA Ronald Ching Wan 馬青雲 |
| 2023.608 | Hong Kong Precision Medicine in Diabetes Initiative | Prof. MA Ronald Ching Wan |
| 2023.146 | Improving Diabetes Care for young patients |
Prof. MA Ronald Ching Wan 馬青雲 |
| 2022.141 | Using data to transform diabetes care and patient lives |
Prof. MA Ronald Ching Wan 馬青雲 |
| 2023.118 | Identifying genetic determinants of drug response in Chinese patients with type 2 diabetes for precision therapeutics |
Prof. MA Ronald Ching Wan 馬青雲 |
| 2023.527 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD |
Prof. MA Ronald Ching Wan 馬青雲 |
| 2019.138 | Establishing the basis for Precision Medicine for Hyperglycaemia in Pregnancy-the Stratification of Hyperglycaemia in Pregnancy (SHIP) Study |
Prof. MA Ronald Ching Wan 馬青雲 |
| 2019.232 | Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes (SOUL) |
Prof. MA Ronald Ching Wan 馬青雲 |
| 2018.476 | The Fenofibrate And Microvascular Events in Type 1 diabetes Eye. A randomised trial to evaluate the efficacy on retinopathy and safety of fenofibrate in adults with type 1 diabetes; A multicentre double-blind placebo-controlled study in Australia and Internationally |
Dr. MA Ronald Ching Wan 馬青雲 |
| 2019.152 | Archival of human biological samples of Investigator-initiated studies in CU-Med Biobank | Prof. MA Ronald Ching Wan |
| 2019.315 | A multicenter, multinational, prospective, interventional, single-arm, Phase IV study evaluating the clinical efficacy and safety of 26 weeks of treatment with insulin glargine 300 U/mL (Gla-300) in patients with Type 2 diabetes mellitus uncontrolled on basal insulin |
Prof. MA Ronald Ching Wan 馬青雲教授 |
| 2020.287 | Effect and safety of semaglutide 2.4 mg once-weekly on weight management in subjects with overweight or obesity |
Dr. MA Ronald Ching Wan 馬青雲 |
| 2020.120 | Type 2 Diabetes Organopathy by Magnetic Resonance Imaging (T2DOM) |
Prof. MA Ronald Ching Wan 馬青雲 |
| 2018.458 | Translating multi-omic discoveries to transform diabetes care and reduce diabetic complications |
Prof. MA Ronald Ching Wan 馬青雲 |
| 2018.475 | A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects with Metabolic Acidosis |
Dr. MA Ronald Ching Wan 馬青雲 |
| 2019.149 | PIONEER 12 China multi-regional clinical trial: Efficacy and safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes mellitus treated with metformin |
Dr. MA Ronald Ching Wan 馬青雲 |
| 2002.119 | Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) Study and Ancillary Studies | Prof. MA Ronald Ching Wan |
| 2008.520 | The effect of maternal hyperglycaemia during pregnancy on mother's future cardiometabolic risk - a follow up on the HAPO study | Prof. MA Ronald Ching Wan |
| 2012.544 | Arterial stiffness indices in mothers of Hyperglycaemia and Adverse Pregnancy outcome (HAPO) study and their children offspring – a HAPO follow-up study | Prof. MA Ronald Ching Wan |
| 2017.449 | Maternal dietary pattern in early pregnancy and the risk of adverse pregnancy and birth outcomes | Prof. MA Ronald Ching Wan |
Page 161 of 254.